Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.85
LPDX's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. LPDX: 2.85 )
LPDX' s 10-Year Cash to Debt Range
Min: 0.66   Max: No Debt
Current: 2.85

Equity to Asset 0.66
LPDX's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. LPDX: 0.66 )
LPDX' s 10-Year Equity to Asset Range
Min: -1.71   Max: 0.71
Current: 0.66

-1.71
0.71
F-Score: 2
Z-Score: 0.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -20.39
LPDX's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. LPDX: -20.39 )
LPDX' s 10-Year Operating margin (%) Range
Min: -20.39   Max: 10.35
Current: -20.39

-20.39
10.35
Net-margin (%) -23.93
LPDX's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. LPDX: -23.93 )
LPDX' s 10-Year Net-margin (%) Range
Min: -23.93   Max: 10.95
Current: -23.93

-23.93
10.95
ROE (%) -26.25
LPDX's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. LPDX: -26.25 )
LPDX' s 10-Year ROE (%) Range
Min: -26.25   Max: -26.25
Current: -26.25

ROA (%) -17.41
LPDX's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. LPDX: -17.41 )
LPDX' s 10-Year ROA (%) Range
Min: -17.41   Max: 21.41
Current: -17.41

-17.41
21.41
ROC (Joel Greenblatt) (%) -70.34
LPDX's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. LPDX: -70.34 )
LPDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -70.34   Max: 94.68
Current: -70.34

-70.34
94.68
» LPDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

LPDX Guru Trades in Q2 2013

Wilbur Ross 724,213 sh (unchged)
» More
Q3 2013

LPDX Guru Trades in Q3 2013

Wilbur Ross 724,213 sh (unchged)
» More
Q4 2013

LPDX Guru Trades in Q4 2013

Jim Simons 79,400 sh (New)
Wilbur Ross 724,213 sh (unchged)
» More
Q1 2014

LPDX Guru Trades in Q1 2014

Jim Simons 120,522 sh (+51.79%)
Wilbur Ross 724,213 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with LPDX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Wilbur Ross 2013-03-31 New Buy0.73%$9.6 - $11.33 $ 3.16-70%724213
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.00
LPDX's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. LPDX: 1.00 )
LPDX' s 10-Year P/B Range
Min: 1   Max: 2.81
Current: 1

1
2.81
P/S 0.90
LPDX's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. LPDX: 0.90 )
LPDX' s 10-Year P/S Range
Min: 0.27   Max: 1.29
Current: 0.9

0.27
1.29
EV-to-EBIT -1.90
LPDX's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. LPDX: -1.90 )
LPDX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -1.9

Current Ratio 2.54
LPDX's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. LPDX: 2.54 )
LPDX' s 10-Year Current Ratio Range
Min: 1.21   Max: 11.5
Current: 2.54

1.21
11.5
Quick Ratio 2.53
LPDX's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. LPDX: 2.53 )
LPDX' s 10-Year Quick Ratio Range
Min: 1.21   Max: 11.47
Current: 2.53

1.21
11.47

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.21
LPDX's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. LPDX: 2.21 )
LPDX' s 10-Year Price/Net Cash Range
Min: 2.23   Max: 4.78
Current: 2.21

2.23
4.78
Price/Net Current Asset Value 1.83
LPDX's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. LPDX: 1.83 )
LPDX' s 10-Year Price/Net Current Asset Value Range
Min: 1.85   Max: 4.09
Current: 1.83

1.85
4.09
Price/Tangible Book 1.06
LPDX's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. LPDX: 1.06 )
LPDX' s 10-Year Price/Tangible Book Range
Min: 1.07   Max: 2.85
Current: 1.06

1.07
2.85
Price/Median PS Value 1.89
LPDX's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. LPDX: 1.89 )
LPDX' s 10-Year Price/Median PS Value Range
Min: 0.82   Max: 2.46
Current: 1.89

0.82
2.46

Business Description

Industry: »
Compare: » details
Traded in other countries:LI0.Germany
LipoScience Inc was incorporated under the laws of North Carolina in June 1994 under the name LipoMed, Inc. and reincorporated under the laws of Delaware in June 2000. In January 2002, it changed its corporate name to LipoScience, Inc. The Company is an in vitro diagnostic company committed to advancing patient care in cardiovascular, metabolic and other diseases using its innovative and proprietary technology platform based on nuclear magnetic resonance, or NMR. The Company's first diagnostic test, the NMR LipoProfile test, is cleared by the FDA and directly measures LDL-P for use in managing cardiovascular disease risk. The Company's strategy is to continue to advance patient care by converting clinicians, and the clinical diagnostic laboratories they use, from traditional cholesterol testing to its NMR LipoProfile test for the management of patients at risk for cardiovascular disease, with the goal of ultimately becoming a clinical standard of care. LIPOSCIENCE, NMR LIPOPROFILE, VANTERA and LIPOTUBE are its registered United States trademarks. The Company's technology platform combines proprietary signal processing algorithms and NMR spectroscopic detection into a clinical analyzer to identify and quantify concentrations of lipoproteins and, potentially, small molecule metabolites. NMR detectors, or spectrometers, analyze a blood plasma or serum sample by subjecting it to a short pulse of radio frequency energy within a strong magnetic field. Each lipoprotein particle within a given diameter range simultaneously emits a distinctive radio frequency signal, similar to distinctive ringing sounds.
» More Articles for LPDX

Headlines

Articles On GuruFocus.com
Distressed Investor Wilbur Ross Buys 2 Stocks May 16 2013 

More From Other Websites
Nasdaq stocks posting largest volume increases Jul 25 2014
Study Published in Atherosclerosis Provides First Large-Scale, Real-World Evidence of Link Between... Jun 24 2014
NMR-based Diabetes Risk Index (DRI) Helps to Identify Normal-weight Individuals at High Risk of... Jun 14 2014
LIPOSCIENCE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 12 2014
LIPOSCIENCE INC Financials May 23 2014
LIPOSCIENCE INC Files SEC form 10-Q, Quarterly Report May 15 2014
LipoScience Nearly Back To Square One May 14 2014
LipoScience's (LPDX) CEO Howard Doran on Q1 2014 Results - Earnings Call Transcript May 12 2014
LipoScience reports Q EPS (13c), consensus (19c) May 12 2014
LIPOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition May 12 2014
LipoScience Announces 2014 First Quarter Financial Results May 12 2014
Q1 2014 LipoScience Inc Earnings Release - After Market Close May 12 2014
LIPOSCIENCE INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in... May 05 2014
LipoScience Announces Cash Management Actions May 05 2014
Outcomes Study Supports Use of LDL Particle Number to Guide Statin Therapy in Patients at Elevated... May 02 2014
LipoScience to Release First Quarter 2014 Financial Results Apr 28 2014
Patients Managed to Target LDL Particle Number Experience Fewer Cardiovascular Events Than Patients... Mar 31 2014
Why LipoScience (LPDX) Stock Hit a One-Year Low Today Mar 28 2014
LIPOSCIENCE INC Files SEC form 10-K, Annual Report Mar 28 2014
Deep Value In This Diagnostic Company Might Attract Activists Mar 27 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide